Input sought on 3D bioprinter

A working group that's bringing a fully-funded 3D bioprinter to the Monash Health Translation Precinct's Cell Therapies Platform is seeking input from researchers as it moves to finalise the purchase of the machine.

The 3D bioprinter is part of a $30 million Biomedical Materials Translational Facility (BMTF) partnership between CSIRO and Monash University, established with funding from Australia’s Science and Industry Endowment Fund (SIEF). 

The Hudson Institute and Monash University’s School of Clinical Sciences have contributed $800,000 of in-kind funding support to house the 3D bioprinter within the Cell Therapies Platform of the MHTP Translational Research Facility.
Funding was announced in early 2015. The working group, including Professor Graham Jenkin and Dr George Thouas, is now seeking feedback from researchers on the specific capabilities they may wish to utilise.

The 3D bioprinter may have the capacity to manufacture:- hard tissue components (bone, joints, cartilage, ligament/tendon)- soft tissue components (skin, muscle, nerves, blood vessels, heart valves, corneas etc)- organ models for research - porous scaffolds for cell and drug delivery- tissue biosensors (eg bionic components)- 3D cell expansion systems (for cell therapies)

The bioprinter is one of three technological platforms that will be based at the BMTF, alongside dual modality (MRI/PET) clinical imaging and a specialist facility for the development and manufacture of next generation biocompatible materials.

If you’re interested in using the 3D bioprinter, or want to learn more about its potential capabilities and how they may enhance your translational research, contact george.thouas@hudson.org.au or graham.jenkin@hudson.org.au